Century Therapeutics
IPSC
61 hedge funds and large institutions have $102M invested in Century Therapeutics in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 13 closing their positions.
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
11.82% more ownership
Funds ownership: 35.66% → 47.48% (+12%)
6% more capital invested
Capital invested by funds: $96.6M → $102M (+$5.7M)
9% less funds holding
Funds holding: 67 → 61 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$17.1M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$9.96M |
| 3 |
CC
Casdin Capital
New York
|
+$6.27M |
| 4 |
VA
VR Adviser
New York
|
+$6.27M |
| 5 |
BlackRock
New York
|
+$4.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$5.11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.33M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.07M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$896K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$389K |
IPSC Hedge Fund Activity: Q2 2024 in Review
61 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q2 2024, worth a combined $102M — up 5.9% from $96.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of IPSC and 7 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 33 added.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $17.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $5.11M sold.
- 61 institutional investors held Century Therapeutics (IPSC) as of Q2 2024, down from 67 in Q1 2024.
- Funds reported $102M of Century Therapeutics stock for Q2 2024, up 5.9% quarter-over-quarter.
- 7 funds opened new Century Therapeutics positions in Q2 2024 and 13 closed out, a net change of -6 holders.
- The largest Century Therapeutics buyer in Q2 2024 was Bain Capital Life Sciences Investors, an estimated $17.1M added.
- The largest Century Therapeutics seller in Q2 2024 was Avidity Partners Management, an estimated $5.11M sold.
Based on aggregated 13F filings for Q2 2024.